Work out a plan for capping prices of all drugs: SC to govt.

1. At a Glance

• On 12 October 2026 the Supreme Court asked the Centre to work out a plan for capping prices of all medicines and medical products. The Centre had told the court it will cap trade margins at 30% only for non-scheduled cancer drugs [1].
• The core issue is the gap between the Price to Retailer (PTR) and the Maximum Retail Price (MRP). For some medicines, especially cancer drugs, the mark-up reached as high as 1,000% [1].
• The legal base for drug price regulation in India is the Drugs (Prices Control) Order (DPCO), 2013 [6]. The regulator is the National Pharmaceutical Pricing Authority (NPPA), which fixes ceiling prices for medicines listed in Schedule-I [5].
• For UPSC this topic touches health (GS-II), pricing regulation (GS-III), the judiciary's role in public health, and the Right to Health under Article 21.

2. Why in the News

• 12 October 2026: Solicitor-General Tushar Mehta told the SC that the Centre will cap trade margins at 30% for both patented and non-patented cancer medicines [1].
• A Bench of Justices Vikram Nath and Sandeep Mehta said the step deserved praise but was not enough. It asked why other medicines and medical devices could not also be brought under the 16% retailer margin in DPCO 2013. The Bench's words: "This is just the tip of the iceberg... What about other drugs" [1].
• Earlier in the case, the Bench had called the excessive PTR-to-MRP mark-ups "broad daylight dacoity" [1].
• The case is being heard on petitions filed by an advocate. The article names them only as "Kishan Chan…" because the excerpt is cut off [1].
• August 2026: reports said the Centre is considering adding Trade Margin Rationalisation (TMR) to DPCO 2013 itself. No timeframe has been set [9].

3. Background & Evolution

• DPCO, 2013: the main legal instrument for regulating drug prices in India [6]. NPPA fixes ceiling prices for Schedule-I drugs under it [5].
• Scheduled vs non-scheduled drugs: NPPA fixes ceiling prices only for Schedule-I drugs [5]. Non-scheduled drugs have no ceiling price, so TMR was used to control their margins [2][4].
• 26 February 2019: NPPA used its extraordinary powers "in public interest" under Para 19 of DPCO 2013 to cap trade margins on 42 non-scheduled anti-cancer medicines [4].
• Cap: 30% [4][8].
• Revised prices took effect from 8 March 2019 [4].
• Initial coverage: 72 formulations, 355 brands [4].

• Projected minimum saving: ₹200 crore a year [4].

• Later NPPA figures: MRPs of 526 brands fell by up to 90% (around 50% on average), with patient savings of about ₹984 crore a year [2][3].

• Example: the MRP of Erlotinib 150 mg (brand Birlotib) fell from ₹9,999 to ₹2,509 [3].

• February 2025: the government told the Lok Sabha that it had fixed ceiling and retail prices to keep cancer drugs affordable [10].

• 2026: TMR had so far been used only as a pilot for the 42 anti-cancer drugs. The Centre is now weighing whether to make it part of DPCO [9].
• October 2026: the SC pushed for TMR to be extended to all drugs and medical products [1].

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic

• TMR leaves the manufacturer's ex-factory price alone and caps the distribution and retail mark-up. That makes it a lighter intervention than full price control [2][4].
• In the 2019 pilot, capping margins led to MRP cuts of up to 90%. This shows that much of the consumer price came from mark-ups along the supply chain, not from production cost [2][3].
• Criticism: for imported, high-cost drugs, a margin cap has little effect. The All India Drug Action Network argued that full price control would work better [7].

Social

• Cancer drugs are a major cause of out-of-pocket expenditure. Cutting MRPs of 526 brands saved patients about ₹984 crore a year [2].
• The SC's question about drugs beyond cancer points to equity for patients with chronic and other illnesses whose medicines are not covered by any cap [1].

Legal / Constitutional

• TMR currently depends on NPPA's Para 19 emergency powers, not on a standing provision in DPCO. That is why there are moves to write TMR into DPCO formally [4][9].
• The SC is acting under its public-interest jurisdiction. The court has also said that making price-controlled medicine available is the government's responsibility [1].
• The case raises a separation-of-powers question: should a court push for a sector-wide pricing policy, or leave it to the executive? [1]

Ethical / Governance

• The Bench described mark-ups of up to 1,000% as "broad daylight dacoity". This raises questions of corporate ethics and how well the regulator is monitoring the market [1].
• NPPA's own savings estimates changed between 2019 and later releases (₹200 crore vs ₹984 crore). Better data and published methods would help transparency [4][2].

Administrative

• Extending TMR to all medicines and medical devices would need large-scale tracking of PTR and MRP across thousands of brands [1].
• Any such move has to be squared with the current Schedule-I ceiling-price system [5][9].

6. Recent Developments (last 12-18 months)

• February 2025: the government told the Lok Sabha it had fixed ceiling and retail prices for cancer drugs [10].
• August 2026: the Centre was reported to be weighing adding TMR to DPCO 2013, with no fixed timeline [9].
• Before October 2026: the SC Bench (Nath and Mehta JJ.) flagged mark-ups of up to 1,000% and called them "broad daylight dacoity" [1].
• 12 October 2026: the Centre announced a 30% trade-margin cap for non-scheduled cancer drugs, patented and non-patented. The SC asked for a plan covering all drugs and medical products [1].

7. Prelims Hooks

• Drug prices in India are regulated under the Drugs (Prices Control) Order, 2013 [6].
• NPPA fixes ceiling prices for drugs in Schedule-I of DPCO 2013 [5].
• TMR was first applied to 42 non-scheduled anti-cancer drugs in February 2019 [4].
• The 2019 TMR was imposed under Para 19 of DPCO 2013, NPPA's extraordinary powers in public interest [4].
• The 2019 TMR cap was 30% [4][8].
• The revised cancer drug prices took effect on 8 March 2019 [4].
• TMR cut the MRP of 526 brands by up to 90% [2].
• Estimated patient savings from cancer drug TMR: about ₹984 crore a year [2].
• DPCO 2013 sets a 16% retailer margin, as cited by the SC [1].
• The SC Bench in the 2026 case: Justices Vikram Nath and Sandeep Mehta [1].
• The SC called mark-ups of up to 1,000% "broad daylight dacoity" [1].
• The proposed 2026 cap covers both patented and non-patented cancer drugs [1].

8. Why One Flat 30% Cap Suits Cheap and Costly Drugs Differently

• A flat percentage gives the biggest rupee profit on the costliest drugs
• The 2026 plan uses one rate, 30%, for every cancer drug, patented or not [1].
• A simple example: 30% on a ₹100 strip is ₹30. On a ₹10,000 vial it is ₹3,000. Yet the work of storing and selling each one is about the same.

• So the cap still lets traders earn the most on the drugs patients can least afford.

• WHO advises a sliding (regressive) margin instead

• The WHO's pricing guideline suggests a regressive mark-up (a margin rate that falls as the price of the medicine rises) [11].

• India's 16% retailer margin in DPCO 2013 and the 30% TMR cap are both flat rates [1][4], so neither follows this advice.

• The cap does nothing about the price the maker sets in the first place

• TMR only controls the gap between PTR and MRP [2].
• For imported, high-cost drugs, most of the price is set before the drug reaches any trader. That is why the All India Drug Action Network called for full price control instead [7].

9. The Risk That Some Medicines Leave the Chemist's Shelf

• If the margin is too thin, sellers may stop stocking a drug
• The WHO warns that medicines can become unavailable when the allowed mark-up does not cover the supplier's cost and expected profit [11].

• Capping one group of cancer drugs carried a small risk. Capping all medicines and medical devices [1] carries a much larger one: a slow-selling drug may simply disappear from small-town pharmacies.

• The evidence that margin caps cut prices is real but uncertain in size

• A WHO evidence review found that mark-up regulation led to statistically significant price cuts. But it could not say with confidence how large those cuts were [12].
• India's 2019 result (up to 90% cuts on 526 brands [2]) came from a sector with extreme mark-ups. That was the market the Bench called "broad daylight dacoity" [1]. Results for ordinary medicines with modest mark-ups may be much smaller.

10. Why the Invoice Price May Not Be the Real Price

• Hidden discounts can defeat a margin cap
• A cap on trade margin is measured from the PTR printed on the invoice.
• The WHO asks countries to make prices transparent, including any rebates and discounts given along the supply chain [11].

• If a rebate is paid off the invoice, the real margin can be bigger than the paper margin, and the regulator never sees it.

• Enforcing a cap on everything needs skill and money

• The WHO notes that tracking prices and enforcing mark-up rules needs highly skilled staff and resources [11].

• NPPA built its record on a fixed list: 42 drugs and a few hundred brands [4][2]. Covering every medicine is a different scale of task, and the note has no data showing NPPA has that capacity.

• The rule must be reviewed, not just announced

• The WHO suggests that mark-up rules be reviewed regularly [11].
• NPPA's own savings figure moved from ₹200 crore to ₹984 crore a year across releases [4][2]. Without a published method, nobody outside can check whether a cap is working.

11. Should the Court Be Setting Drug Policy? The Case Against, and Its Answer

• The strongest objection
• Pricing medicines is a technical, economic choice. It needs cost data, supply-chain studies and trade-offs that courts are not built to weigh.

• Under separation of powers, this is the executive's job. A court pushing every drug and device under one cap could cause the very shortages the WHO warns about [11].

• What is right about it

• The Bench has no cost data of its own. Its comparison with the 16% DPCO margin [1] is a starting question, not a worked-out policy.

• The answer

• The court did not fix a number. It asked the Centre to work out a plan [1]. The design is left to the executive.
• TMR was the executive's own tool. NPPA used it in 2019 under Para 19 [4]. Yet seven years later it was still only a pilot, with no timeline to make it permanent [9].
• When the executive's tool works but stays unused, a court asking "why not more?" under the Right to Health (Article 21) is pressing for action, not taking over policy.

12. What Other Countries Do Differently

• Many countries cap margins only in government hospitals
• China and Kuwait allow zero mark-up on medicines sold at public health facilities [12].

• This is easier to enforce, because the state is both buyer and seller.

• Some go further and cap private pharmacies

• Oman and Kuwait set maximum mark-ups at private retail pharmacies [12].

• India's 2026 debate is about this harder case. Its 1,000% mark-ups were found in drugs sold through the private trade chain [1].

• The lesson for India

• A margin cap works best as one part of a package. The WHO advises using it together with other pricing policies, not on its own [11].

13. What a Workable Plan Should Contain

• The Centre should write TMR into DPCO 2013, not rely on emergency powers

• Para 19 is meant for extraordinary situations [4]. A rule covering all medicines needs a standing legal base, which the Centre is already considering [9].

• NPPA should use price slabs, not one flat rate

• Lower-priced drugs could get a higher percentage margin, and costly drugs a lower one, as the WHO's regressive model suggests [11].

• This protects the chemist's income on cheap medicines and stops windfall profits on expensive ones.

• NPPA should require disclosure of discounts and publish its data

• This means PTR, MRP and rebates by brand, with a review on a fixed cycle, in line with WHO advice [11].

• Patented and imported drugs need a separate tool

• A margin cap cannot touch the maker's price [7]. For these drugs the government must look to price negotiation or the Patents Act route (compulsory licensing).

14. Anchors for Answers

• Data: Trade mark-ups of up to 1,000% between PTR and MRP on some cancer drugs [1]; the 2019 TMR cut MRPs of 526 brands by up to 90%, saving about ₹984 crore a year [2]
• Report/Committee: WHO Guideline on Country Pharmaceutical Pricing Policies, 2020: recommends regressive mark-ups, used together with other pricing policies [13][11]
• Law/Case: DPCO 2013, Para 19 (NPPA's extraordinary powers in public interest) [4]; Article 21 (Right to Health); SC Bench of Vikram Nath and Sandeep Mehta JJ., October 2026 [1]
• Comparison: Oman and Kuwait cap mark-ups at private retail pharmacies; China and Kuwait allow zero mark-up at public facilities [12]
• Scheme: Pradhan Mantri Bhartiya Janaushadhi Pariyojana: makes cheap generics available directly, which works alongside price caps

15. Mains Relevance

• GS-II: issues relating to Health; government policies and interventions; judicial activism and structure of the judiciary.
• GS-III: the pharmaceutical industry, regulation and pricing; inclusive growth.
• Possible question stems: 1. "Trade margin rationalisation is a market-friendly alternative to full price control of medicines." Critically examine this statement in light of the 2019 cancer drug experience and the Supreme Court's 2026 observations. 2. Discuss whether the judiciary should direct the executive on drug pricing policy. How can affordable medicines be balanced with the incentive to innovate? 3. High out-of-pocket health spending remains a barrier to Universal Health Coverage in India. Evaluate the role of the DPCO 2013 framework in addressing it.

16. Related Topics to Study Next

• National List of Essential Medicines (NLEM): it decides which drugs go into DPCO Schedule-I and so get ceiling prices.
• Essential Commodities Act, 1955: the parent statute under which DPCO is issued.
• Jan Aushadhi (PMBJP): a supply-side way to make medicines affordable, alongside price caps.
• Medical devices regulation and pricing: the SC specifically asked for devices to be included.
• Patents Act, Section 3(d) and compulsory licensing: relevant because the 2026 cap covers patented drugs.
• Right to Health under Article 21: the constitutional basis for judicial action on drug access.
• Ayushman Bharat PM-JAY and out-of-pocket expenditure: the other side of the health-affordability question.

17. NCERT Concepts to Revise

• Price control (Economy): The whole case is about government capping drug prices and trade margins under DPCO 2013.
• Maximum Retail Price (Economy): The dispute is the gap between price to retailer and the printed MRP, with mark-ups up to 1,000%.
• Essential commodities (Economy): DPCO is issued under the Essential Commodities Act, which lets government control supply and prices of essential goods.
• Right to health (Polity): Right to health under Article 21 is the constitutional basis for the court pushing on affordable medicines.
• Judicial activism (Polity): The Supreme Court is pressing the Centre to extend price caps beyond cancer drugs to all medicines.
• Separation of powers (Polity): Raises the question of whether courts should direct the executive on sector-wide drug pricing policy.

18. Common Errors / Trap Areas

• DPCO year: the current order is 2013, not 1995. TMR for cancer drugs came in 2019, not 2013 [4][6].
• Scheduled vs non-scheduled: NPPA's ceiling prices apply to Schedule-I drugs. TMR was used for non-scheduled drugs [4][5].
• The two margin figures: the 16% retailer margin is a DPCO provision. The 30% is the TMR cap on trade margin. Do not mix them up [1][4].
• Legal basis: the 2019 TMR used Para 19 emergency powers. As of 2026, TMR is not yet a standing part of DPCO [4][9].
• Savings figures: the ₹200 crore projection (2019) and the ₹984 crore figure (later) come from different NPPA releases [4][2].